MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.

ABSTRACT:

Background

Ovarian cancer (OC) is the most lethal gynecological malignancy and the second leading cause of cancer-related death in women. Treatment with PARP inhibitors (PARPi), such as Olaparib, has been recently introduced for OC patients, but resistance may occur and underlying mechanisms are still poorly understood. The aim of this study is to identify target genes within the tumor cells that might cause resistance to Olaparib. We focused on Neuropilin 1 (NRP1), a transmembrane receptor expressed in OC and correlated with poor survival, which has been also proposed as a key molecule in OC multidrug resistance.

Methods

Using three OC cell lines (UWB, UWB-BRCA and SKOV3) as model systems, we evaluated the biological and molecular effects of Olaparib on OC cell growth, cell

SUBMITTER: Vescarelli E 

PROVIDER: S-EPMC6939329 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature